SEMA

Overview

Semaglutide is being widely researched for its potential in metabolic regulation, including obesity, diabetes, and cardiovascular health. It mimics natural GLP-1 activity to enhance insulin secretion, promote weight loss, and regulate appetite.

Product Research

• Type 2 Diabetes Management

  Semaglutide has shown significant reduction in HbA1c levels in individuals with type 2 diabetes, making it a strong candidate in glycemic regulation models [1].

• Obesity and Weight Management

  Clinical trials have confirmed semaglutide’s ability to induce substantial weight loss in subjects with obesity or overweight, surpassing placebo effects [2].

• Cardiovascular Outcomes

  A landmark trial demonstrated a reduction in major adverse cardiovascular events in patients using semaglutide, particularly in those with existing type 2 diabetes and cardiovascular risk [3].

• Non-Alcoholic Fatty Liver Disease (NAFLD)

  Research suggests that semaglutide improves liver enzyme profiles and reduces liver fat, supporting its role in metabolic liver disease models [4].

• Long-Term Weight Maintenance

  In long-term studies like STEP 5, semaglutide has shown sustained weight loss over a 2-year period, highlighting its potential for chronic obesity research [5].

Disclaimer

This product is intended for laboratory research and development purposes only. It is not approved for human consumption, medical, or veterinary use. All information is provided for scientific reference only and should be used under proper research conditions by qualified professionals.

Referenced Citations

1. Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis – PubMed
2. Semaglutide for the treatment of obesity – PubMed
3. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes – PubMed
4. Efficacy and safety of semaglutide in non-alcoholic fatty liver disease – PubMed
5. Two-year effects of semaglutide in adults with overweight or obesity – PubMed